Effect of Sodium Phosphocreatine in adjuvant treatment of chronic heart failure and its impact on cardiac function,hypersensitive C reactive protein and N-terminal B brain natriuretic peptide
LI Shu-qing
Department of Cardiology,People′s Hospital in Liaoning Province,Shenyang 110016,China
Abstract：Objective To explore the clinical effect of application of Sodium Phosphocreatine in the adjuvant treatment of chronic heart failure(CHF).MethodsAltogether 98 CHF patients who were admitted to our hospital from June 2014 to June 2017 were selected as subjects and divided into two groups according to the random number table method.The control group(49 cases)was treated with routine symptomatic therapies,such as heart strengthening,diuresis promotion and vasodilation;while,the observation group (49 cases)was given intravenous drip of Sodium Phosphocreatine on this basis of control group.The clinical efficacy and changes of pre-and post-treatment cardiac function index(including left ventricular ejection fraction[LVEF],left ventricular end systolic/diastolic diameter[LVESD and LVEDD]),serological index(including hypersensitive C reactive protein[hs-CRP]and N terminal B brain natriuretic peptide[NT-proBNP])were compared between two groups.Results The post-treatment total effective rate of the observation group was 89.80%,which was significantly higher than that of the control group of 73.47%,the difference was statistically significant(P<0.05).The post-treatment LVEF values of the two groups were significantly higher than those before treatment,the post-treatment LVESD and LVEDD values of the two groups were significantly lower than those before treatment,the differences were statistically significant(P<0.05).And the post-treatment LVEF values of the observation group was significantly higher than control group,the post-treatment LVESD and LVEDD values of the observation group were significantly lower than control group,the differences were statistically significant(P<0.05).The post-treatment serum hs-CRP and NT-proBNP of the two groups were significantly lower than those before treatment,with statistically significant differences(P<0.01),and the post-treatment serum hs-CRP and NT-proBNP of observation group were lower than those of control group,with statistically significant differences(P<0.01).Conclusion Application of sodium phosphocreatine in treatment of CHF can relieve patients′symptoms,reduce the myocardium injury and improve the heart function,which is worthy of clinical application.
李淑清. 磷酸肌酸钠辅助治疗慢性心力衰竭的效果及对心功能和超敏C反应蛋白、N端B型脑尿钠肽的影响[J]. 中国当代医药, 2018, 25(28): 55-57转65.
LI Shu-qing. Effect of Sodium Phosphocreatine in adjuvant treatment of chronic heart failure and its impact on cardiac function,hypersensitive C reactive protein and N-terminal B brain natriuretic peptide. 中国当代医药, 2018, 25(28): 55-57转65.
京公网安备 11010502046607号